ID   AL4A1_HUMAN             Reviewed;         563 AA.
AC   P30038; A8K1Q7; B4DGE4; D2D4A3; Q16882; Q53HU4; Q5JNV6; Q8IZ38;
AC   Q96IF0; Q9UDI6;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 3.
DT   10-MAY-2017, entry version 182.
DE   RecName: Full=Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial;
DE            Short=P5C dehydrogenase;
DE            EC=1.2.1.88;
DE   AltName: Full=Aldehyde dehydrogenase family 4 member A1;
DE   AltName: Full=L-glutamate gamma-semialdehyde dehydrogenase;
DE   Flags: Precursor;
GN   Name=ALDH4A1; Synonyms=ALDH4, P5CDH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney, and Retina;
RX   PubMed=8621661; DOI=10.1074/jbc.271.16.9795;
RA   Hu C.-A., Lin W.-W., Valle D.;
RT   "Cloning, characterization, and expression of cDNAs encoding human
RT   delta 1-pyrroline-5-carboxylate dehydrogenase.";
RL   J. Biol. Chem. 271:9795-9800(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Stagos D., Vasiliou V.;
RT   "A novel transcript variant of human ALDH4A1 gene.";
RL   Submitted (NOV-2008) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ILE-470.
RC   TISSUE=Amygdala, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Adipose tissue;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-470.
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=1395511;
RA   Hempel J., Eckey R., Berie D., Romovacek H., Agarwal D.P.,
RA   Goedde H.W.;
RT   "Human liver glutamic gamma-semialdehyde dehydrogenase: structural
RT   relationship to the yeast enzyme.";
RL   Comp. Biochem. Physiol. 102B:791-793(1992).
RN   [9]
RP   PROTEIN SEQUENCE OF 25-35.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 94-99; 105-113; 125-139; 176-191; 251-273;
RP   339-347; 354-365 AND 510-526.
RC   TISSUE=Liver;
RX   PubMed=8493898;
RA   Agarwal D.P., Eckey R., Hempel J., Goedde H.W.;
RT   "Human liver high Km aldehyde dehydrogenase (ALDH4): properties and
RT   structural relationship to the glutamic gamma-semialdehyde
RT   dehydrogenase.";
RL   Adv. Exp. Med. Biol. 328:191-197(1993).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 18-563 OF WILD-TYPE; MUTANT
RP   ALA-352 AND VARIANT HYRPRO2 LEU-352, CATALYTIC ACTIVITY, FUNCTION,
RP   PATHWAY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, ACTIVE SITE,
RP   CHARACTERIZATION OF VARIANT HYRPRO2 LEU-352, AND MUTAGENESIS OF
RP   SER-352.
RX   PubMed=22516612; DOI=10.1016/j.jmb.2012.04.010;
RA   Srivastava D., Singh R.K., Moxley M.A., Henzl M.T., Becker D.F.,
RA   Tanner J.J.;
RT   "The three-dimensional structural basis of type II hyperprolinemia.";
RL   J. Mol. Biol. 420:176-189(2012).
RN   [16]
RP   VARIANT HYRPRO2 LEU-352, AND VARIANT LEU-16.
RX   PubMed=9700195; DOI=10.1093/hmg/7.9.1411;
RA   Geraghty M.T., Vaughn D., Nicholson A.J., Lin W.-W.,
RA   Jimenez-Sanchez G., Obie C., Flynn M.P., Valle D., Hu C.-A.A.;
RT   "Mutations in the Delta1-pyrroline 5-carboxylate dehydrogenase gene
RT   cause type II hyperprolinemia.";
RL   Hum. Mol. Genet. 7:1411-1415(1998).
CC   -!- FUNCTION: Irreversible conversion of delta-1-pyrroline-5-
CC       carboxylate (P5C), derived either from proline or ornithine, to
CC       glutamate. This is a necessary step in the pathway interconnecting
CC       the urea and tricarboxylic acid cycles. The preferred substrate is
CC       glutamic gamma-semialdehyde, other substrates include succinic,
CC       glutaric and adipic semialdehydes. {ECO:0000269|PubMed:22516612}.
CC   -!- CATALYTIC ACTIVITY: L-glutamate 5-semialdehyde + NAD(+) + H(2)O =
CC       L-glutamate + NADH. {ECO:0000269|PubMed:22516612}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=100 uM for NAD {ECO:0000269|PubMed:22516612};
CC         KM=32 uM for L-pyrroline-5-carboxylate
CC         {ECO:0000269|PubMed:22516612};
CC   -!- PATHWAY: Amino-acid degradation; L-proline degradation into L-
CC       glutamate; L-glutamate from L-proline: step 2/2.
CC       {ECO:0000269|PubMed:22516612}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:22516612}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-3926971, EBI-3926971;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P30038-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30038-2; Sequence=VSP_043785;
CC       Name=3;
CC         IsoId=P30038-3; Sequence=VSP_047732;
CC   -!- TISSUE SPECIFICITY: Highest expression is found in liver followed
CC       by skeletal muscle, kidney, heart, brain, placenta, lung and
CC       pancreas.
CC   -!- DISEASE: Hyperprolinemia 2 (HYRPRO2) [MIM:239510]: An inborn error
CC       of proline metabolism resulting in elevated plasma levels of
CC       proline and delta-1-pyrroline-5-carboxylate (P5C). The condition
CC       is considered to be benign, but affected individuals can exhibit
CC       neurological manifestations that vary in severity. Clinical signs
CC       include seizures, intellectual deficit and mild developmental
CC       delay. {ECO:0000269|PubMed:22516612, ECO:0000269|PubMed:9700195}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the aldehyde dehydrogenase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U24267; AAC50501.1; -; mRNA.
DR   EMBL; U24266; AAC50500.1; -; mRNA.
DR   EMBL; FJ462711; ACN89883.1; -; mRNA.
DR   EMBL; AK289972; BAF82661.1; -; mRNA.
DR   EMBL; AK294552; BAG57755.1; -; mRNA.
DR   EMBL; AK222486; BAD96206.1; -; mRNA.
DR   EMBL; AL080251; CAI23417.1; -; Genomic_DNA.
DR   EMBL; AL954340; CAI23417.1; JOINED; Genomic_DNA.
DR   EMBL; AL954340; CAI39493.1; -; Genomic_DNA.
DR   EMBL; AL080251; CAI39493.1; JOINED; Genomic_DNA.
DR   EMBL; BX537160; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471134; EAW94858.1; -; Genomic_DNA.
DR   EMBL; BC007581; AAH07581.1; -; mRNA.
DR   EMBL; BC023600; AAH23600.1; -; mRNA.
DR   CCDS; CCDS188.1; -. [P30038-1]
DR   CCDS; CCDS53272.1; -. [P30038-2]
DR   CCDS; CCDS81273.1; -. [P30038-3]
DR   RefSeq; NP_001154976.1; NM_001161504.1. [P30038-2]
DR   RefSeq; NP_001306147.1; NM_001319218.1. [P30038-3]
DR   RefSeq; NP_003739.2; NM_003748.3. [P30038-1]
DR   RefSeq; NP_733844.1; NM_170726.2. [P30038-1]
DR   UniGene; Hs.77448; -.
DR   PDB; 3V9G; X-ray; 2.50 A; A/B/C/D=18-563.
DR   PDB; 3V9H; X-ray; 2.40 A; A/B/C/D=18-563.
DR   PDB; 3V9I; X-ray; 2.85 A; A/B/C/D=18-563.
DR   PDB; 4OE5; X-ray; 1.95 A; A/B/C/D=18-563.
DR   PDBsum; 3V9G; -.
DR   PDBsum; 3V9H; -.
DR   PDBsum; 3V9I; -.
DR   PDBsum; 4OE5; -.
DR   ProteinModelPortal; P30038; -.
DR   SMR; P30038; -.
DR   BioGrid; 114208; 23.
DR   IntAct; P30038; 2.
DR   STRING; 9606.ENSP00000290597; -.
DR   ChEMBL; CHEMBL3414418; -.
DR   DrugBank; DB00157; NADH.
DR   iPTMnet; P30038; -.
DR   PhosphoSitePlus; P30038; -.
DR   BioMuta; ALDH4A1; -.
DR   DMDM; 62511241; -.
DR   OGP; P30038; -.
DR   SWISS-2DPAGE; P30038; -.
DR   EPD; P30038; -.
DR   MaxQB; P30038; -.
DR   PaxDb; P30038; -.
DR   PeptideAtlas; P30038; -.
DR   PRIDE; P30038; -.
DR   DNASU; 8659; -.
DR   Ensembl; ENST00000290597; ENSP00000290597; ENSG00000159423. [P30038-1]
DR   Ensembl; ENST00000375341; ENSP00000364490; ENSG00000159423. [P30038-1]
DR   Ensembl; ENST00000538309; ENSP00000442988; ENSG00000159423. [P30038-2]
DR   Ensembl; ENST00000538839; ENSP00000446071; ENSG00000159423. [P30038-3]
DR   GeneID; 8659; -.
DR   KEGG; hsa:8659; -.
DR   UCSC; uc001bbb.4; human. [P30038-1]
DR   CTD; 8659; -.
DR   DisGeNET; 8659; -.
DR   GeneCards; ALDH4A1; -.
DR   HGNC; HGNC:406; ALDH4A1.
DR   HPA; CAB004645; -.
DR   HPA; HPA006401; -.
DR   MalaCards; ALDH4A1; -.
DR   MIM; 239510; phenotype.
DR   MIM; 606811; gene.
DR   neXtProt; NX_P30038; -.
DR   OpenTargets; ENSG00000159423; -.
DR   Orphanet; 79101; Hyperprolinemia type 2.
DR   PharmGKB; PA24701; -.
DR   eggNOG; KOG2455; Eukaryota.
DR   eggNOG; COG1012; LUCA.
DR   GeneTree; ENSGT00560000077335; -.
DR   HOVERGEN; HBG050484; -.
DR   InParanoid; P30038; -.
DR   KO; K00294; -.
DR   OMA; KIWEKAA; -.
DR   OrthoDB; EOG091G085N; -.
DR   PhylomeDB; P30038; -.
DR   TreeFam; TF300481; -.
DR   BioCyc; MetaCyc:HS14757-MONOMER; -.
DR   BRENDA; 1.2.1.88; 2681.
DR   Reactome; R-HSA-70688; Proline catabolism.
DR   SABIO-RK; P30038; -.
DR   UniPathway; UPA00261; UER00374.
DR   ChiTaRS; ALDH4A1; human.
DR   GeneWiki; Aldehyde_dehydrogenase_4_family,_member_A1; -.
DR   GenomeRNAi; 8659; -.
DR   PRO; PR:P30038; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000159423; -.
DR   CleanEx; HS_ALDH4A1; -.
DR   ExpressionAtlas; P30038; baseline and differential.
DR   Genevisible; P30038; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0003842; F:1-pyrroline-5-carboxylate dehydrogenase activity; EXP:Reactome.
DR   GO; GO:0004029; F:aldehyde dehydrogenase (NAD) activity; IDA:CACAO.
DR   GO; GO:0009055; F:electron carrier activity; TAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019470; P:4-hydroxyproline catabolic process; TAS:BHF-UCL.
DR   GO; GO:0006537; P:glutamate biosynthetic process; IEA:InterPro.
DR   GO; GO:0006561; P:proline biosynthetic process; IEA:InterPro.
DR   GO; GO:0006562; P:proline catabolic process; TAS:Reactome.
DR   GO; GO:0010133; P:proline catabolic process to glutamate; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006560; P:proline metabolic process; TAS:ProtInc.
DR   CDD; cd07123; ALDH_F4-17_P5CDH; 1.
DR   Gene3D; 3.40.605.10; -; 1.
DR   InterPro; IPR016161; Ald_DH/histidinol_DH.
DR   InterPro; IPR016160; Ald_DH_CS_CYS.
DR   InterPro; IPR029510; Ald_DH_CS_GLU.
DR   InterPro; IPR016162; Ald_DH_N.
DR   InterPro; IPR015590; Aldehyde_DH_dom.
DR   InterPro; IPR005931; P5CDH/ALDH4A1.
DR   Pfam; PF00171; Aldedh; 1.
DR   SUPFAM; SSF53720; SSF53720; 1.
DR   TIGRFAMs; TIGR01236; D1pyr5carbox1; 1.
DR   PROSITE; PS00070; ALDEHYDE_DEHYDR_CYS; 1.
DR   PROSITE; PS00687; ALDEHYDE_DEHYDR_GLU; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Mitochondrion; NAD;
KW   Oxidoreductase; Phosphoprotein; Polymorphism; Proline metabolism;
KW   Reference proteome; Transit peptide.
FT   TRANSIT       1     24       Mitochondrion.
FT                                {ECO:0000269|PubMed:1286669}.
FT   CHAIN        25    563       Delta-1-pyrroline-5-carboxylate
FT                                dehydrogenase, mitochondrial.
FT                                /FTId=PRO_0000007173.
FT   NP_BIND     286    290       NAD. {ECO:0000250}.
FT   ACT_SITE    314    314       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10007, ECO:0000255|PROSITE-
FT                                ProRule:PRU10008}.
FT   ACT_SITE    348    348       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10007, ECO:0000255|PROSITE-
FT                                ProRule:PRU10008,
FT                                ECO:0000269|PubMed:22516612}.
FT   BINDING     208    208       NAD. {ECO:0000250}.
FT   BINDING     233    233       NAD. {ECO:0000250}.
FT   BINDING     447    447       NAD. {ECO:0000250}.
FT   BINDING     513    513       Substrate. {ECO:0000250}.
FT   SITE        211    211       Transition state stabilizer.
FT                                {ECO:0000250}.
FT   MOD_RES      31     31       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES      44     44       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      52     52       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES      93     93       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES      93     93       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES      99     99       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES      99     99       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     114    114       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     114    114       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     130    130       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     130    130       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     175    175       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     175    175       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     318    318       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     347    347       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     365    365       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     376    376       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     395    395       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     462    462       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     509    509       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     509    509       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     531    531       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   MOD_RES     552    552       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CHT0}.
FT   VAR_SEQ       1     60       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043785.
FT   VAR_SEQ     396    446       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_047732.
FT   VARIANT      16     16       P -> L (in allele ALDH4A1*4;
FT                                dbSNP:rs146450609).
FT                                {ECO:0000269|PubMed:9700195}.
FT                                /FTId=VAR_002259.
FT   VARIANT     352    352       S -> L (in HYRPRO2; allele ALDH4A1*3;
FT                                loss of enzyme activity;
FT                                dbSNP:rs137852937).
FT                                {ECO:0000269|PubMed:22516612,
FT                                ECO:0000269|PubMed:9700195}.
FT                                /FTId=VAR_002260.
FT   VARIANT     470    470       V -> I (in dbSNP:rs2230709).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_029337.
FT   VARIANT     473    473       T -> A (in dbSNP:rs6695033).
FT                                /FTId=VAR_048903.
FT   MUTAGEN     352    352       S->A: Reduced affinity for NAD. No effect
FT                                on enzyme activity.
FT                                {ECO:0000269|PubMed:22516612}.
FT   CONFLICT     68     68       V -> M (in Ref. 1; AAC50501/AAC50500).
FT                                {ECO:0000305}.
FT   CONFLICT    189    191       PPS -> LPY (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    189    189       P -> L (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    226    226       M -> I (in Ref. 4; BAD96206).
FT                                {ECO:0000305}.
FT   CONFLICT    271    271       D -> E (in Ref. 8; AA sequence and 10; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT    354    354       L -> K (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    376    376       K -> R (in Ref. 4; BAD96206).
FT                                {ECO:0000305}.
FT   CONFLICT    524    526       RAS -> GSA (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND       24     30       {ECO:0000244|PDB:3V9H}.
FT   HELIX        45     57       {ECO:0000244|PDB:4OE5}.
FT   STRAND       62     64       {ECO:0000244|PDB:4OE5}.
FT   STRAND       66     68       {ECO:0000244|PDB:4OE5}.
FT   STRAND       71     73       {ECO:0000244|PDB:4OE5}.
FT   STRAND       78     83       {ECO:0000244|PDB:4OE5}.
FT   STRAND       86     95       {ECO:0000244|PDB:4OE5}.
FT   HELIX        99    118       {ECO:0000244|PDB:4OE5}.
FT   HELIX       121    136       {ECO:0000244|PDB:4OE5}.
FT   TURN        137    139       {ECO:0000244|PDB:4OE5}.
FT   HELIX       140    151       {ECO:0000244|PDB:4OE5}.
FT   HELIX       155    165       {ECO:0000244|PDB:4OE5}.
FT   HELIX       167    180       {ECO:0000244|PDB:4OE5}.
FT   STRAND      192    199       {ECO:0000244|PDB:4OE5}.
FT   STRAND      201    207       {ECO:0000244|PDB:4OE5}.
FT   HELIX       217    225       {ECO:0000244|PDB:4OE5}.
FT   STRAND      229    233       {ECO:0000244|PDB:4OE5}.
FT   HELIX       236    238       {ECO:0000244|PDB:4OE5}.
FT   HELIX       239    251       {ECO:0000244|PDB:4OE5}.
FT   STRAND      258    261       {ECO:0000244|PDB:4OE5}.
FT   HELIX       266    274       {ECO:0000244|PDB:4OE5}.
FT   STRAND      279    286       {ECO:0000244|PDB:4OE5}.
FT   HELIX       288    300       {ECO:0000244|PDB:4OE5}.
FT   HELIX       301    304       {ECO:0000244|PDB:4OE5}.
FT   STRAND      310    315       {ECO:0000244|PDB:4OE5}.
FT   STRAND      319    323       {ECO:0000244|PDB:4OE5}.
FT   HELIX       329    341       {ECO:0000244|PDB:4OE5}.
FT   HELIX       342    345       {ECO:0000244|PDB:4OE5}.
FT   STRAND      351    357       {ECO:0000244|PDB:4OE5}.
FT   TURN        358    360       {ECO:0000244|PDB:4OE5}.
FT   HELIX       361    372       {ECO:0000244|PDB:4OE5}.
FT   TURN        380    382       {ECO:0000244|PDB:4OE5}.
FT   HELIX       394    409       {ECO:0000244|PDB:4OE5}.
FT   STRAND      413    417       {ECO:0000244|PDB:4OE5}.
FT   STRAND      424    426       {ECO:0000244|PDB:4OE5}.
FT   STRAND      432    437       {ECO:0000244|PDB:4OE5}.
FT   HELIX       442    445       {ECO:0000244|PDB:4OE5}.
FT   STRAND      450    458       {ECO:0000244|PDB:4OE5}.
FT   HELIX       460    462       {ECO:0000244|PDB:4OE5}.
FT   HELIX       463    472       {ECO:0000244|PDB:4OE5}.
FT   STRAND      475    477       {ECO:0000244|PDB:3V9I}.
FT   STRAND      479    483       {ECO:0000244|PDB:4OE5}.
FT   HELIX       487    496       {ECO:0000244|PDB:4OE5}.
FT   TURN        497    500       {ECO:0000244|PDB:4OE5}.
FT   STRAND      502    508       {ECO:0000244|PDB:4OE5}.
FT   TURN        515    517       {ECO:0000244|PDB:3V9H}.
FT   HELIX       528    530       {ECO:0000244|PDB:4OE5}.
FT   STRAND      534    536       {ECO:0000244|PDB:3V9H}.
FT   HELIX       537    541       {ECO:0000244|PDB:4OE5}.
FT   STRAND      542    549       {ECO:0000244|PDB:4OE5}.
FT   HELIX       560    562       {ECO:0000244|PDB:3V9H}.
SQ   SEQUENCE   563 AA;  61719 MW;  4D964771B7DB5FFD CRC64;
     MLLPAPALRR ALLSRPWTGA GLRWKHTSSL KVANEPVLAF TQGSPERDAL QKALKDLKGR
     MEAIPCVVGD EEVWTSDVQY QVSPFNHGHK VAKFCYADKS LLNKAIEAAL AARKEWDLKP
     IADRAQIFLK AADMLSGPRR AEILAKTMVG QGKTVIQAEI DAAAELIDFF RFNAKYAVEL
     EGQQPISVPP STNSTVYRGL EGFVAAISPF NFTAIGGNLA GAPALMGNVV LWKPSDTAML
     ASYAVYRILR EAGLPPNIIQ FVPADGPLFG DTVTSSEHLC GINFTGSVPT FKHLWKQVAQ
     NLDRFHTFPR LAGECGGKNF HFVHRSADVE SVVSGTLRSA FEYGGQKCSA CSRLYVPHSL
     WPQIKGRLLE EHSRIKVGDP AEDFGTFFSA VIDAKSFARI KKWLEHARSS PSLTILAGGK
     CDDSVGYFVE PCIVESKDPQ EPIMKEEIFG PVLSVYVYPD DKYKETLQLV DSTTSYGLTG
     AVFSQDKDVV QEATKVLRNA AGNFYINDKS TGSIVGQQPF GGARASGTND KPGGPHYILR
     WTSPQVIKET HKPLGDWSYA YMQ
//
